US61023L2079
US61023L2079
Monopar Therapeutics Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±295.9% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.5x as much as the broader market.
Beta (Market Relation)
1.51x
Above averageVolatility (5Y p.a.)
295.9% p.a.
5-Year HorizonMax Drawdown (5Y)
-94.5%
5-Year HorizonSharpe Ratio
0.09
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -14.8% |
| 3 Years | 375.3% | -67.3% | 0.56 | +213.5% |
| 5 Years | 295.9% | -94.5% | 0.09 | +29.6% |
| 10 Years | — | — | — | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 1.51 indicates above-average volatility compared to the broader market.
Elevated Short-Term Volatility: 3Y volatility (375.3%) is noticeably higher than the 5Y average (295.9%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (295.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -94.5% in the extended horizon.